23 March 2009: NorDiag has appointed Biocentric as exclusive distributor in the field of infectious diseases for France.

Biocentric is an integrated biotechnology company involved in R&D, production and distribution of reagents, kits and instruments for clinical diagnostics. The company has grown to become a strong and established player in the French market with superior track records for distribution of clinical diagnostic products from well known companies. The company's products are used by clinical laboratories, hospitals and leading research institutes. The company's headquarters are in Bandol, France.

Mårten Wigstøl, CEO in NorDiag, comments: "This is the third distributor we sign up with so far in 2009.  Fast coverage of Europe with a skilled sales network has high priority. We are in the process of launching our desktop instrument Arrow to the market. With proven applications with large market potential and new applications in pipeline, we have the tool box in place for geographical expansion and sales growth in 2009."

NorDiag has already established a solid foothold and market share in Scandinavia and the strategy is to use the Scandinavian market as a reference market for further commercialization and geographic expansion. Biocentric is expected to give a major contribution to this process, with their network, competence and industry knowledge.

For further information, please contact:
CEO Mårten Wigstøl                      
Phone + 47 911 65775

About NorDiag:
NorDiag is a biotechnology company developing, manufacturing and marketing automated solutions, instruments and tests, for diagnostic of infectious diseases and cancer. The Company`s core competence is isolation of bacterial and human DNA from difficult clinical samples, and the Company has established a solid market share in the Scandinavian market for sexually transmitted infections. The company has similar applications for Tuberculosis and MRSA. An application for respiratory pathogens is under development. NorDiag is also developing a test that shall contribute to early diagnosis of colorectal cancer. NorDiag was founded in 2003 and has its headquarters in Oslo - Norway. The Company has offices and laboratories in Bergen - Norway, Stockholm - Sweden and West Chester (PA) - USA. The group has 36 employees. NorDiag is listed on Oslo Stock Exchange with the ticker NORD.

For further information - www.nordiag.com

Read the notice in Norwegian here